VERASTEM INC (VSTM) Stock News
NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD
VSTM Latest News, Press Relases and Analysis
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Deutsche Bank Reaffirms Buy Rating on Roblox Amid Google Deal
Deutsche Bank reaffirmed its Buy rating on Roblox Corporation (NYSE:RBLX) shares on May 19, with a price target of $78. The report followed the announcement of a new partnership between Roblox and Google for Rewarded Video Ads. With plans to scale distribution even further in the near future, Roblox’s partnership with Google will utilize AdMob […]
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology Announces $75 million Private Placement
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
